






**Supplementary Figure S1.** Multivariate analysis showing metabolic profiles across all GT3-treated NHPs: (A) short term (first 24 h) metabolomics negative, (B) long-term (2 days to 20 days) metabolomics negative, (C) short term lipidomics positive (D) long term lipidomics positive (E) short term lipidomics negative and (F) long term lipidomics negative. All groups demonstrated minimal separation, indicating no significant changes.


**A****C****B****D**

**Supplementary Figure S2.** TIC overlays for QC samples in (A) lipidomics negative, (B) lipidomics positive, (C) metabolomics negative, and (D) metabolomics positive with internal standard coefficient of variance of 5.8%, 18.05%, 5.66% and 25.48%, respectively.




Supplementary Figure S3. Trend lines for top 20 dysregulated biomarkers, for each GT3 dose.

A




B



**Supplementary Figure S4.** Multivariate analysis showing metabolic profiles (A) across all GT3-treated NHPs, separated by gender and (B) A subset of time points that were shown to have maximal separation against control.





Supplementary Figure S5. Trend lines for top 20 dysregulated biomarkers delineated by gender.